Published in Curr Heart Fail Rep on September 01, 2010
Soluble guanylate cyclase α1-deficient mice: a novel murine model for primary open angle glaucoma. PLoS One (2013) 0.96
Endothelial actions of atrial and B-type natriuretic peptides. Br J Pharmacol (2012) 0.92
cGMP becomes a drug target. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.85
Update on the Management of Acute Decompensated Heart Failure. Curr Treat Options Cardiovasc Med (2011) 0.84
Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma. Front Mol Neurosci (2014) 0.83
Natriuretic Peptides and Cardiometabolic Health. Circ J (2015) 0.79
Association of genetic variation with gene expression and protein abundance within the natriuretic peptide pathway. J Cardiovasc Transl Res (2013) 0.79
In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator. Pulm Pharmacol Ther (2012) 0.79
In-vivo evaluation of an in situ polymer precipitation delivery system for a novel natriuretic peptide. PLoS One (2013) 0.78
Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide. J Card Fail (2014) 0.77
Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions. Eur Heart J Cardiovasc Pharmacother (2015) 0.76
Pharmacogenomics of the Natriuretic Peptide System in Heart Failure. Curr Heart Fail Rep (2017) 0.75
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA (2003) 13.79
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell (2005) 5.71
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol (2002) 3.68
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA (2011) 2.86
Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension (2007) 2.77
Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res (2002) 2.51
Limitations of estimating glomerular filtration rate from serum creatinine in the general population. Mayo Clin Proc (2006) 2.37
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med (2008) 2.14
Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol (2008) 2.04
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2006) 1.98
Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. J Card Fail (2008) 1.89
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A (2005) 1.85
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension (2007) 1.84
Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation (2004) 1.82
Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2011) 1.78
The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide. Hypertension (2010) 1.74
Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation (2007) 1.72
Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation (2007) 1.69
Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation (2004) 1.67
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol (2012) 1.66
BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail (2004) 1.66
Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol (2011) 1.59
A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol (2009) 1.53
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension (2006) 1.52
Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction. Hypertension (2007) 1.50
Participation bias in a population-based echocardiography study. Ann Epidemiol (2004) 1.48
Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J (2009) 1.47
Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation (2003) 1.44
Natriuretic peptides and therapeutic applications. Heart Fail Rev (2007) 1.44
The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol (2010) 1.43
Biology of the natriuretic peptides. Am J Cardiol (2008) 1.41
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail (2005) 1.39
Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation (2007) 1.34
Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation (2011) 1.33
Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol (2006) 1.31
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J (2013) 1.30
HIV promoter integration site primarily modulates transcriptional burst size rather than frequency. PLoS Comput Biol (2010) 1.30
B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation (2005) 1.28
Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure. Circulation (2005) 1.27
The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol (2004) 1.27
Membrane guanylyl cyclase receptors: an update. Trends Endocrinol Metab (2006) 1.27
Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol (2006) 1.25
Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail (2004) 1.24
Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. Am J Physiol Regul Integr Comp Physiol (2011) 1.24
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J (2012) 1.24
Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail (2011) 1.24
Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol (2007) 1.23
Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.23
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol (2005) 1.23
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) (2013) 1.21
A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol (2011) 1.20
Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. Clin Chem (2010) 1.17
Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem (2008) 1.16
B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc (2005) 1.15
Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol (2006) 1.14
Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin (2009) 1.12
Current progress of RNA aptamer-based therapeutics. Front Genet (2012) 1.12
BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol (2006) 1.10
Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev (2004) 1.10
Progression of preclinical diastolic dysfunction to the development of symptoms. Heart (2010) 1.09
The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. J Card Fail (2008) 1.08
HIV evades RNA interference directed at TAR by an indirect compensatory mechanism. Cell Host Microbe (2008) 1.07
Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation (2011) 1.07
Pharmacology of vasopressin antagonists. Heart Fail Rev (2008) 1.06
Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension. Mayo Clin Proc (2012) 1.06
Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". Circulation (2010) 1.06
Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol (2005) 1.05
Ventricular structure and function in aged dogs with renal hypertension: a model of experimental diastolic heart failure. Circulation (2005) 1.05
Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J Am Coll Cardiol (2002) 1.04
Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension. Circulation (2008) 1.04
TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail (2012) 1.03
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail (2013) 1.02
Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study. Hypertension (2013) 1.02
Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol (2009) 1.02
Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol (2003) 1.02
Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. J Am Coll Cardiol (2009) 1.00
The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays. Mayo Clin Proc (2011) 0.99
Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs (2004) 0.99
Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol (2006) 0.98
The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc (2013) 0.98
Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin Proc (2011) 0.97
Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Cardiovasc Drug Rev (2007) 0.96
Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. Clin Chem (2011) 0.95
Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res (2002) 0.95
Defining high-sensitivity cardiac troponin concentrations in the community. Clin Chem (2013) 0.95
Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. Am J Physiol Regul Integr Comp Physiol (2012) 0.94
Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension (2007) 0.93
Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated cardiomyopathies. Clin Cardiol (2007) 0.93
The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population. Diabetes Care (2013) 0.91
CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One (2012) 0.91